KRAS: From undruggable to a druggable Cancer Target
D Uprety, AA Adjei - Cancer treatment reviews, 2020 - Elsevier
RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Understanding the profile of oncogene and tumor suppressor gene mutations with their
interactions and impact on the prognosis of multiple myeloma (MM) can improve the …
interactions and impact on the prognosis of multiple myeloma (MM) can improve the …
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
J Xu, LJ Chen, SS Yang, Y Sun, W Wu… - Proceedings of the …, 2019 - National Acad Sciences
Relapsed and refractory (R/R) multiple myeloma (MM) patients have very poor prognosis.
Chimeric antigen receptor modified T (CAR T) cells is an emerging approach in treating …
Chimeric antigen receptor modified T (CAR T) cells is an emerging approach in treating …
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial… - Blood, The Journal …, 2016 - ashpublications.org
Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …
Prognostic and predictive biomarker developments in multiple myeloma
CT Wallington-Beddoe, RL Mynott - Journal of hematology & oncology, 2021 - Springer
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …
decision-making, or prediction, are needed since patients are currently managed in a similar …
Genomic complexity of multiple myeloma and its clinical implications
Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …
Co-evolution of tumor and immune cells during progression of multiple myeloma
Multiple myeloma (MM) is characterized by the uncontrolled proliferation of plasma cells.
Despite recent treatment advances, it is still incurable as disease progression is not fully …
Despite recent treatment advances, it is still incurable as disease progression is not fully …
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …